Clinical Trial Update: Therapeutic Cancer Vaccine (AST-301, pNGVL3-hICD) in Patients With Breast Cancer [Phase 2]

View source ↗

Summary

Phase 2 trial of AST-301 (pNGVL3-hICD) for breast cancer has been terminated. The study termination halts further development of this therapeutic cancer vaccine…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Breast Cancer

Drugs mentioned

• AST-301 (pNGVL3-hICD)

Snippet

Sponsor: Aston Sci. Inc. | Conditions: Breast Cancer | Phase 2 | Status: TERMINATED